We are pround to announce our membership to the Pistoia Alliance. This global, not-for-profit organization is working to lower barriers to innovation in life science and healthcare R&D through pre-competitive collaboration. hubs.ly/H0J4FNZ0

What should you do when building machine learning models, and you have many more features than you have samples? Read more at: hubs.ly/H0JmHq00

A very interesting article on the changing landscape of clinical trial management. Particularly interesting is the observation: "Data will need to be cleaned continuously as it comes in, rather than waiting until a study closes out". hubs.ly/H0K9YN70

This is an interesting exercise... the author used AI to identify and recruit experts for the prediction of trends. We are particularly fond of #38, #56 and (our own) #63. Saving the best for last? hubs.ly/H0KPVbB0

This is the first installment in a series that will explain various ways that the quality of a binary classification model can be summarized as metrics. The Confusion Matrix - Binary Classification — BioSymetrics hubs.ly/H0KWNRX0

Sema4 and BioSymetrics, a phenomics-driven drug discovery company, are collaborating to accelerate the advancement of new medicines for #patients and #pharmaceutical companies. Learn more from our press release and video: hubs.la/Q014DMWs0.

This week we announced a #data-driven #drugdiscovery partnership with @Sema4 to advance precision medicine and initiate up to 10 new therapeutics programs. #AI #MachineLearning Learn more here: biosymetrics.com/sema4-partners…

Our partnership with Sema4 will leverage a combined 23 million longitudinal patient records, rich with #clinical and #genomics data. Read more about the partnership here: biosymetrics.com/sema4-partners…

Last week we announced a #drugdiscovery partnership with Sema4 to initiate up to 10 new therapeutics programs for #patients and #pharmaceutical companies. Sema4 Founder and CEO Eric Schadt, PhD, said about the deal:

Congrats to our #drugdiscovery partner Sema4

The #Phenograph is a linkage map that connects #phenotypes to genes to diseases to drugs, enabling quick #translation of findings between model systems and humans. To learn more, read the interview with our Co-Founder & CSO Gabe. #AI #biotech biosymetrics.com/what-is-the-ph…

The #Phenograph is a powerful linkage map that lets us traverse human #disease #biology and better translate #clinical and #experimental data into novel drug discoveries, using #machinelearning. Learn more here: biosymetrics.com/what-is-the-ph… #phenomics #genomics #drugdiscovery

It's #BIO2022 and we're excited to be in #SanDiego! Find us: 1) Presenting an Overview of our #phenomics-driven approach to #drugdiscovery Wednesday at 1:45 pm in Presentation Theater 1 2) On Alliance for Artificial Intelligence in Healthcare panel "Real World Successes of AI in Healthcare" Wednesday at 7:30 am

Our team is at #BIO2022 discussing our next generation approach to #AI-powered #DrugDiscovery, leveraging #Phenomics, and across advancing programs in #cardiovascular, #neurological and rare disorders. To learn more catch our live Company Overview tomorrow at 1:45 pm.

We'll be there! #BIO2022

A great event - thanks to Alliance for Artificial Intelligence in Healthcare for including our Chief Strategy Officer Stacie Calad-Thomson as part of this stirring panel on real-world traction in AI for healthcare #BIO2022

#PMWC22 is next week and you can find our Chief Strategy Officer & Head of Drug Discovery Stacie Calad-Thomson on a panel on the Role of #MachineLearning in Drug Discovery and Development along w/ execs from Genentech Eli Lilly and Immunai. #precisionmedicine

We're excited to announce that Dave Kokel, PhD, has joined our team as VP of Discovery Biology. Dave is an accomplished scientist, researcher and pioneer in phenotypic #drugdiscovery. To learn more, read the interview with Dave. #scientists #AI #biotech biosymetrics.com/the-pheno-type…

*NEW RESEARCH* We used our proprietary #Phenograph to navigate from #phenotypes to genes to druggable targets and identify six targets associated with #anosmia, or loss of sense of smell, a common symptom of #COVID19. Read our paper on bioRxiv: biorxiv.org/content/10.110…

Physician-scientist Calum MacRae Calum MacRae is one of our scientific advisors and an evangelist of our approach to #phenotypic #drugdiscovery to uncover novel targets. Learn more about Calum's career inspiration and predictions for modern drug discovery: biosymetrics.com/the-phenotype-…